SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community grapples with mixed sentiments amidst ongoing price stagnation, despite some believing a potential merger involving Zero Hash and Mastercard, alongside progress on the Clarity Act, could be catalysts. Many holders are expressing frustration over consistent declines, while others are actively accumulating, pointing to Flexa's real-world utility with major merchants and recent patents as reasons for long-term optimism. The debate rages between those who see it as a foundational payment collateral token and those who fear it's a 'dead project' that continually disappoints.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing highly polarized sentiment, with many in the community expressing frustration over significant losses and year-end tax-loss selling contributing to downward pressure. Despite widespread discussions questioning its utility and sustained underperformance relative to other major cryptocurrencies, a dedicated segment of holders maintains long-term conviction, eagerly anticipating a future resurgence.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending with a massive volume surge and price rally following news of a strategic manufacturing partnership aimed at scaling production of its drug screening reader for future U.S. market entry. The community is intensely divided, with bulls pointing to the low float and the positive impact of a $10 million private placement on its balance sheet, while bears express significant concern over dilution, the company's reverse split history, and the offering's terms.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to massive trading volume and a significant price surge, sparking intense community discussion around its low-float SPAC nature. Traders are actively anticipating further upward movement and a potential squeeze, drawing parallels to other recently explosive micro-cap plays that have experienced rapid ascents.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is generating significant buzz as a low-float SPAC, with traders actively discussing its potential for a substantial price run. The community is drawing strong parallels to recent 'shell company rippers' like ESHA, anticipating a considerable upward movement fueled by limited circulating shares and growing speculative interest.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its new integration with a Stripe-owned fiat anchor, which enables seamless, compliant bank-to-stablecoin transfers at a verified 11 million transactions per second. The community sees it as a potentially undervalued Layer 1 blockchain, poised to become essential financial infrastructure for institutions by offering high-speed, regulated settlement rails. This focus on enterprise-grade plumbing for global finance differentiates it from many other crypto projects.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant upward momentum as the FDA granted Priority Review for its AXS-05 in Alzheimer's disease agitation, with a PDUFA target date of April 30, and confirmed a clear path for its AXS-12 narcolepsy treatment. This major regulatory progress, alongside robust Auvelity sales growth and numerous analyst price target increases, has ignited strong bullish sentiment across the community. Many are celebrating long-term holdings and are optimistic about Axsome's potential to capitalize on substantial market opportunities in CNS disorders.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending with significant community anticipation for the start of a new yearly cycle, driving strong bullish sentiment for substantial long-term gains. Many investors are actively accumulating, citing historical patterns that suggest an imminent upward trajectory. The discussion is marked by strong convictions from bulls, despite ongoing skepticism from bears regarding its immediate outlook.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending amid intense community debate, primarily driven by widespread shareholder frustration with CEO Richard Paulson and the board, whom many accuse of continuous value destruction and mismanagement. Recent financing and a reverse stock split, while extending the cash runway, have amplified concerns about dilution and executive accountability. Despite this pervasive negative sentiment toward leadership, significant bullish options activity and anticipation for upcoming Phase 3 trial readouts in Myelofibrosis and Endometrial Cancer highlight an underlying belief in the company's scientific potential, contingent on a change in management.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is trending due to recent strategic moves, including pipeline expansion through acquisitions and manufacturing advancements for its lead anticoagulant candidate, Tecarfarin. The market is weighing the potential of these developments, including analyst-assigned price targets and FDA designations, against community concerns about cash burn, dilution, and the company's ability to fund pivotal Phase 3 trials. This creates a polarized discussion, highlighting the high-stakes nature of micro-cap biopharma investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should State Street SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?

Shares of Dick’s Sporting Goods (DKS) climbed on Wednesday afternoon despite Truist lowering its price target by $15, flagging lingering investor caution over the company’s planned deal with Foot Locker and economic risks in the second half of the fiscal year.&nbsp;Truist trimmed its price target to $230, down from $245, and maintained a ‘Buy’ rating on the shares, as per TheFly.According to the brokerage, the company’s first-quarter results and full-year guidance met or slightly exceeded expectations, but the planned acquisition of Foot Locker (FL) remains an overhang.Truist noted ongoing concerns about macroeconomic pressures in the second half of 2025. It While investors may need more time to assess the Foot Locker deal, Truist expects Dick’s competitive strengths to continue supporting the stock.Dick’s Sporting Goods Executive Chairman Edward Stack said during the company’s earnings call on Wednesday that the deal is expected to generate synergy gains of $100 million to $125 million over the medium term.&nbsp;The Foot Locker deal is expected to allow Dick’s Sporting Goods to enter international markets for the first time. The transaction is expected to close in the second half of the year.&nbsp;The sporting goods giant also reaffirmed its full-year guidance, including the expected impact of all current tariffs. However, the outlook does not account for acquisition-related costs, investment costs, or results from the Foot Locker acquisition.Dick’s Sporting Goods reported earnings per share (EPS) of $3.37, beating analyst estimates of $3.21, according to Koyfin data.Its revenue rose 5% year-on-year, coming in at $3.17 billion, above the Wall Street estimate of $3.12 billion.&nbsp;Comparable sales rose 4.5% in the first quarter (Q1), marking the fifth straight quarter of over 4% growth, driven by omnichannel experience and product assortment.&nbsp;<a href="https://stocktwits.com/symbol/DKS">Dick’s Sporting Goods stock</a> was up 1.7% in afternoon trade on Wednesday. The shares are down 23% this year, and have fallen over 7% in the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/senator-elizabeth-warren-questions-pentagon-ai-contracting/ch0o8o4RbsV">Senator Elizabeth Warren Reportedly Questions Pentagon AI Contracting Amid Reports Of Elon Musk’s Grok Use In US Agencies</a>

A Dick's Sporting Goods store at Selinsgrove, Pennsylvania, United States. (Photo by Paul Weaver/SOPA Images/LightRocket via Getty Images)

Dick’s Sporting Goods Stock Gains Even As Truist Lowers Target, Warns Foot Locker Deal Remains A Drag

Truist trimmed its price target on Dick’s Sporting Goods to $230, down from $245, and maintained a ‘Buy’ rating on the shares.

Equity

Truist trimmed its price target on Dick’s Sporting Goods to $230, down from $245, and maintained a ‘Buy’ rating on the shares.


Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?

Shares of Dick’s Sporting Goods Inc. (<a class="mention" data-mention="$DKS" data-symbol-id="DKS" href="https://stocktwits.com/symbol/DKS" target="_blank">$DKS</a>) were up 0.5% on Tuesday morning (11:27 a.m. ET) after rising more than 6% in the pre-market session, following stronger-than-expected third-quarter earnings and improved EPS guidance, lifting retail sentiment ahead of the holiday shopping season.The sporting goods retailer said its net sales for Q3 stood at $3.06 billion, which was above the &nbsp;$3.03 billion that Wall Street analysts were expecting. Its earnings per share (EPS) stood at $2.75, beating consensus estimates of $2.68 quoted by analysts.The company attributed its strong performance to an “excellent back-to-school season” and “continued focus” on its strategic pillars.The sporting goods retailer has raised its full-year 2024 EPS guidance to between $13.65 and $13.95, up from $13.55 to $13.90 issued previously. &nbsp;Comparable sales growth rate for Q3 stood at 4.2%. Comparable sales growth for the year has been revised to a range of 3.6% to 4.2%, up from the earlier 2.5% to 3.5%.“We are very proud of our Q3 results and our performance year-to-date…We believe our differentiated product, quality service and powerful omni-channel experience will resonate well with our athletes this holiday season," Lauren Hobart, president and CEO, said in a statement.Retail sentiment on the stock turned ‘extremely bullish’ (92/100) from ‘bearish’ (59/100) a day ago, marking a year-high. Message volume stayed in the ‘extremely high’ (96/100) zone, also the highest in a year.<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_26_at_10_40_37_PM_f0571c25a2.png" alt="Screenshot 2024-11-26 at 10.40.37 PM.png" width="1304" height="290"><figcaption>DKS sentiment meter and message volumes on Nov 26 as of 11:45 am ET| Source: Stocktwits</figcaption></figure>In November, the company’s board also declared a quarterly dividend of $1.10 per share for its common stock and class B common stock, payable in cash on Dec. 27, said the statement.Several Stocktwits users were surprised by the volatility of the stock movement given the numbers, with one user predicting a short squeeze.<stembedurl>https://stocktwits.com/Vacationforever25/message/594115543</stembedurl>DKS stock is up 47.42% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.

Retail sentiment on the stock turned ‘extremely bullish’| Source: Wikimedia Commons

Dick’s Sporting Goods Stock In Focus After Q3 Earnings Beat: Retail Activity Hits Year-High

The company raised its full year guidance for comparable sales growth to a range of 3.6% to 4.2%, up from 2.5% to 3.5% previously.

SPMD
SPDR Portfolio S&P 400 Mid Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SPMD News

SPMDSPDR Portfolio S&P 400 Mid Cap ETF